NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ZURA

Zura Bio Ltd

Jul 03 • 02:47PM ET

1.13

Dollar change +0.01
Percentage change 0.89	%

Healthcare • Biotechnology • USA • NASD

Peers: AMGN REGN VRTX BIIB GILD INCY ALNY BMRN IONS NBIX

| Held by: VXF VTWO SCHA IWC IWM VTWG IWO VTHR MSSM

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.76	Insider Own	37.57%	Shs Outstand	68.37M	Perf Week	-1.74%
Market Cap	69.92M	Forward P/E	-	EPS next Y	-0.80	Insider Trans	0.00%	Shs Float	38.63M	Perf Month	5.61%
Enterprise Value	-87.45M	PEG	-	EPS next Q	-0.19	Inst Own	60.97%	Short Float	6.91%	Perf Quarter	-3.42%
Income	-62.10M	P/S	-	EPS this Y	-25.83%	Inst Trans	1.43%	Short Ratio	4.78	Perf Half Y	-55.69%
Sales	0.00M	P/B	0.56	EPS next Y	-5.52%	ROA	-47.23%	Short Interest	2.67M	Perf YTD	-54.80%
Book/sh	2.02	P/C	0.41	EPS next 5Y	-18.03%	ROE	-62.34%	52W High	5.07 -77.71%	Perf Year	-68.87%
Cash/sh	2.76	P/FCF	-	EPS past 3/5Y	- -	ROIC	-44.93%	52W Low	0.97 16.49%	Perf 3Y	-88.56%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.37% 8.24%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	53.92%	Oper. Margin	-	ATR (14)	0.09	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	8.14	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	48.73	Recom	1.33
Dividend Gr. 3/5Y	- -	Current Ratio	8.14	EPS Q/Q	-1102.56%	SMA20	-2.84%	Beta	-0.11	Target Price	13.67
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	-5.21%	Rel Volume	0.23	Prev Close	1.12
Employees	30	LT Debt/Eq	0.00	Earnings	May 08 BMO	SMA200	-49.16%	Avg Volume	558.70K	Price	1.13
IPO	Sep 03, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-19.80% -	Trades		Volume	129,512	Change	0.89%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-04-24	Initiated	Leerink Partners	Outperform	$15
Sep-05-24	Initiated	H.C. Wainwright	Neutral	$5
May-03-24	Initiated	Piper Sandler	Overweight	$26
Oct-10-23	Initiated	Ladenburg Thalmann	Buy	$10
Aug-25-23	Initiated	Oppenheimer	Outperform	$17
Jun-22-23	Initiated	Guggenheim	Buy	$20
Jun-14-23	Initiated	Chardan Capital Markets	Buy	$14
May-24-23	Initiated	Raymond James	Strong Buy	$20

Jul-01-25 06:30AM	Zura Bio Announces Chief Financial Officer Transition (Business Wire)
May-27-25 06:30AM	Zura Bio to Present at the Jefferies Global Healthcare Conference (Business Wire)
May-20-25 06:30AM	Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa (Business Wire)
May-08-25 06:30AM	Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates (Business Wire)
Mar-25-25 06:30AM	Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates (Business Wire) +10.37%
06:30AM	Loading…
Feb-24-25 06:30AM	Zura Bio to Present at the Leerink Partners Global Healthcare Conference (Business Wire)
Dec-23-24 06:30AM	Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis (Business Wire)
Nov-25-24 06:30AM	Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference (Business Wire) +12.09%
Nov-14-24 04:30PM	Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis (Business Wire) -17.81% -12.22%
Nov-07-24 06:30AM	Zura Bio Reports Third Quarter 2024 Financial Results and Recent Corporate Updates (Business Wire)
Oct-30-24 06:30AM	Zura Bio to Participate in Two Upcoming Investor Conferences in November (Business Wire)
Sep-03-24 06:00AM	Zura Bio to Present at Three Upcoming Investor Conferences in September (Business Wire)
Aug-13-24 09:21AM	Zura Bio Reports Second Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
Aug-12-24 04:05PM	Zura Bio Completes Exchange Offer and Consent Solicitation and Notice to Exercise Right to Exchange Remaining Outstanding Warrants (Business Wire)
Aug-09-24 04:05PM	Zura Bio Announces Expiration and Results of Exchange Offer and Consent Solicitation Relating to its Warrants (Business Wire)
08:00AM	Loading…
Aug-01-24 08:00AM	Sagimet Biosciences Announces Appointment of Anne Phillips and Jennifer Jarrett to its Board of Directors (GlobeNewswire)
Jul-12-24 06:10AM	Zura Bio Commences Warrant Exchange Offer and Consent Solicitation (Business Wire) -6.08%
06:08AM	The 3 Most Undervalued Biotech Stocks to Buy in July 2024 (InvestorPlace)
Jun-14-24 06:00AM	Zura Bio Presents Data for the Tibulizumab (ZB-106) Program at EULAR 2024 (Business Wire)
Jun-06-24 06:00AM	Zura Bio Forms Scientific Advisory Board with Prominent Specialists in Rheumatology, Dermatology, and Immunology (Business Wire) -8.11%
Jun-03-24 06:00AM	Zura Bio to Present Data Exploring the Expanded Potential of Tibulizumab (ZB-106) into Sjogren's Syndrome and Rheumatoid Arthritis at EULAR 2024 (Business Wire) -7.05%
May-31-24 09:55AM	Wall Street Analysts Predict a 235.2% Upside in Zura Bio Limited (ZURA): Here's What You Should Know (Zacks)
May-29-24 06:00AM	Zura Bio Announces Participation in June Investor Conferences (Business Wire)
May-24-24 06:18AM	3 Penny Stocks to Buy Now: May 2024 (InvestorPlace)
May-15-24 09:55AM	How Much Upside is Left in Zura Bio Limited (ZURA)? Wall Street Analysts Think 248.84% (Zacks)
May-14-24 12:00PM	Zura Bio Limited (ZURA) Upgraded to Buy: Here's What You Should Know (Zacks) +7.72%
May-12-24 03:26PM	13 Penny Stocks with Insider Buying in 2024 (Insider Monkey)
May-10-24 03:14PM	Zura Bio Ltd (ZURA) Q1 2024 Earnings: Financial and Strategic Developments (GuruFocus.com)
May-09-24 01:56PM	ZURA Stock Earnings: Zura Bio Beats EPS for Q2 2024 (InvestorPlace)
06:00AM	Zura Bio Reports First Quarter 2024 Financial Results and Recent Business Highlights (Business Wire)
02:18AM	Loading…
Apr-25-24 02:18AM	Director Amit Munshi Acquires 159,744 Shares of Zura Bio Ltd (ZURA) (GuruFocus.com) +9.37%
Apr-18-24 09:22AM	Zura Bio Announces Oversubscribed $112.5 Million Private Placement (Business Wire) +17.89%
Apr-08-24 06:00AM	Zura Bio Announces Robert Lisicki as CEO and Director (Business Wire)
Mar-28-24 11:54AM	ZURA Stock Earnings: Zura Bio Misses EPS for Q4 2023 (InvestorPlace) +10.78%
06:00AM	Zura Bio Reports Full Year 2023 Financial Results, Business Highlights, and Appoints Robert Lisicki as Chief Executive Officer (Business Wire)
Mar-04-24 06:00AM	Zura Bio Announces Participation at March Conferences (Business Wire)
Feb-02-24 06:00AM	Zura Bio Announces Participation at February Investor Conferences (Business Wire) +6.11%
Jan-08-24 06:00AM	Zura Bio Continues to Strengthen Leadership with Appointment of Robert Lisicki as President and Kiran Nistala as CMO (Business Wire)
Jan-03-24 06:00AM	Zura Bio to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Dermatology Summit (Business Wire)
Dec-04-23 06:00AM	Zura Bio Announces Two Immunology Abstracts Presented at the World Allergy Congress in Bangkok (Business Wire)
Nov-14-23 06:00AM	Zura Bio Appoints Arnout Ploos van Amstel to its Board of Directors (Business Wire) +10.00%
Nov-13-23 06:30AM	Zura Bio Reports Third Quarter 2023 Financial Results and Recent Business Highlights (Business Wire) -6.54%
Sep-12-23 05:00AM	Zura Bio Enters into Sponsored Research Agreement with Benaroya Research Institute (Business Wire)
Sep-05-23 08:55PM	Oppenheimer Says These 2 Stocks Could Double Your Money Heres Why They Could Jump (TipRanks)
Aug-25-23 09:42AM	Netflix upgraded, Olaplex downgraded: Wall Street's top analyst calls (The Fly)
Aug-14-23 07:00AM	Zura Bio Reports Second Quarter 2023 Financial Results and Recent Business Highlights (Business Wire)
Jun-23-23 06:30AM	Zura Bio to Join the Russell 2000® and Russell 3000® Indexes (Business Wire) -5.69%
Jun-06-23 06:34AM	Daily Vickers Top Buyers & Sellers for 06/06/2023 (Argus Research) +16.80%
04:00AM	Zura Bio Completes Approximately $80 Million Financing with the Focus on Advancing ZB-106, a Potential First-in-class Anti-IL-17 and Anti-BAFF Dual Antagonist (Business Wire)
Jun-01-23 10:20AM	Load Up, Says Raymond James About These 2 Strong Buy Stocks (TipRanks) +10.82%
Apr-27-23 07:39AM	Zura Bio Announces $80 Million Financing and the Licensing of Tibulizumab (ZB-106), a Potential First-in-Class anti-IL-17 and anti-BAFF Dual Antagonist for Autoimmune Diseases (Business Wire)
Apr-14-23 05:00AM	Zura Bio Announces Appointment of Chief Scientific Officer (Business Wire)
Mar-27-23 09:35AM	Zura Bio Limited Announces Share Redemptions and Lock-up Agreement (Business Wire) -42.76%
Mar-21-23 06:13AM	Zura Bio Limited Announces Closing of Business Combination with JATT Acquisition Corp (Business Wire) -11.27%

Zura Bio Ltd. is a clinical-stage biotechnology company, which engages in the development of novel medicines for immune disorders. It focuses on the development of ZB-168, a treatment for Alopecia Areata and other inflammatory diseases. The company was founded by Someit Sidhu on January 18, 2022 and is headquartered in Henderson, NV.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Thiara Parvinder	Director	Nov 25 '24	Sale	2.73	1,001,633	2,734,458	0	Nov 27 04:15 PM
Thiara Parvinder	Director	Sep 11 '24	Sale	2.70	3,800,000	10,260,000	1,001,633	Sep 13 04:15 PM
Sidhu Someit	Director	Sep 04 '24	Sale	3.87	51,728	200,187	2,085,418	Sep 06 05:37 PM
Sidhu Someit	Director	Sep 04 '24	Proposed Sale	3.85	52,000	200,000		Sep 04 12:55 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZURA

Zura Bio Ltd

Upgrade your FINVIZ experience